Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To evaluate the anti-tumor activity of cabazitaxel by assessing objective tumor response
rate (ORR) at the recommended dose (RD) when administered as a single agent every 3 weeks in
patients with advanced gastric adenocarcinoma who have failed prior chemotherapy regimens
Secondary Objectives:
- To determine the RD of cabazitaxel when administered as a single agent every 3 weeks
- To evaluate safety of cabazitaxel when administered as a single agent every 3 weeks
- To estimate the overall survival (OS) and progression free survival (PFS)
- To assess the pharmacokinetics (PK) profile of cabazitaxel in part 1